IHMA (International Health Management Associates) is a leading brand that specializes in antimicrobial drug development and support services. With over 30 years of experience, IHMA offers a comprehensive range of technical capabilities and domain expertise in all phases of antimicrobial drug development, including drug discovery, clinical development, regulatory submissions, and commercialization. Their services include specialized microbiology laboratory services, antimicrobial resistance surveillance, clinical trials, and more.

IHMA stands out as a premier provider of antimicrobial drug development studies, partnering with clients across the globe in the biotechnology, pharmaceutical, and diagnostic industries. Their state-of-the-art laboratories in the US and Europe enable them to deliver first-class testing and data, as well as sound economic frameworks. With a fully integrated approach, IHMA supports all aspects of drug development, providing clients access to globally available facilities, extensive scientific expertise, and ongoing project support.

Backed by strong statistics, including relationships with over 1,500 healthcare institutions in 80 countries and a repository of hundreds of thousands of clinically relevant bacterial isolates, IHMA demonstrates its commitment to successful drug development, commercialization, and post-marketing pathways. Led by a team of experienced professionals, including President & CEO Jack L. Johnson and Chief Scientific Officer Daniel F.

Sahm, IHMA continues to offer collaboration and flexibility to ensure ongoing success for its clients worldwide